Insmed Incorporated (NASDAQ:INSM) Stake Lifted by WCM Investment Management LLC

WCM Investment Management LLC grew its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 58.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 148,330 shares of the biopharmaceutical company’s stock after buying an additional 54,806 shares during the period. WCM Investment Management LLC owned 0.09% of Insmed worth $10,751,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in INSM. V Square Quantitative Management LLC acquired a new stake in Insmed in the third quarter worth approximately $30,000. EntryPoint Capital LLC acquired a new stake in shares of Insmed during the 1st quarter valued at $33,000. GAMMA Investing LLC lifted its holdings in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 287 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares during the period.

Insmed Stock Down 2.3 %

INSM opened at $71.82 on Tuesday. The firm has a market cap of $12.85 billion, a price-to-earnings ratio of -12.94 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm’s 50-day simple moving average is $72.51 and its 200-day simple moving average is $63.39. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The company’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period last year, the firm posted ($1.10) earnings per share. Equities research analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on INSM. StockNews.com cut Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Monday, September 9th. UBS Group boosted their price target on Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Bank of America boosted their target price on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, Stifel Nicolaus increased their target price on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and an average price target of $83.07.

Insider Buying and Selling at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the transaction, the insider now directly owns 100,100 shares in the company, valued at approximately $7,157,150. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is currently owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.